Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Hospitalization of Patients With Early COVID-19 by an Anti-inflammatory Drug-based Home-treatment Algorithm:a Three-months, Pragmatic, Cluster Randomized, Open-label, Blinded Endpoint (PROBE) Trial

NCT05413642 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT05413642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Hospitalization of Patients With Early COVID-19 by an Anti-inflammatory Drug-based Home-treatment Algorithm:a Three-months, Pragmatic, Cluster Randomized, Open-label, Blinded Endpoint (PROBE) Trial
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 3
Overall status
Withdrawn
Start date
July 1, 2023
Completion date
February 6, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19